(Q40990086)

25 September 2017

1 reference

title

New therapeutic approaches in sepsis: a critical review (English)

1 reference

25 September 2017

0 references

3

C L Sprung

1 reference

25 September 2017

1

L A Eidelman

1 reference

25 September 2017

R Pizov

2

1 reference

25 September 2017

publication date

1 November 1995

1 reference

25 September 2017

published in

Intensive Care Medicine

1 reference

25 September 2017

volume

21 Suppl 2

1 reference

25 September 2017

page(s)

S269-72

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01740766

25 September 2017

exact match

0 references

cites work

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01740766

Immunotherapy of gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01740766

Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01740766

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

21 January 2018

1 reference

12 December 2020

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

1 reference

12 December 2020

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

1 reference

12 December 2020

Why have new effective therapies for sepsis not been developed?

1 reference

12 December 2020

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

1 reference

12 December 2020

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

1 reference

12 December 2020

Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies

1 reference

12 December 2020

Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis

1 reference

12 December 2020

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

12 December 2020

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

12 December 2020

The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study

1 reference

12 December 2020

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01740766

1 reference

25 September 2017

1 reference